An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Celltrion
- 09 May 2017 Planned primary completion date changed from 1 Jul 2017 to 23 Feb 2019.
- 09 May 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 16 Sep 2016 New trial record